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TUMEFACTIVE MULTIPLE SCLEROSIS LESIONS
UNDERFINGOLIMODTREATMENT
Fingolimod is an oral sphingosine 1-phosphate re-
ceptor modulator that prevents recirculation of lym-
phocyte subsets from lymph nodes. It decreases the
number of relapses, slows the progression of disabil-
ity, and improves MRI endpoints in patients with
relapsing-remitting multiple sclerosis (RRMS).1 In-
frequent but specific side effects are bradycardia, leu-
kopenia, and macular edema.
Case report. In November 2010, a 23-year-old
woman with RRMS since September 2007 started
fingolimod 0.5 mg per day in the setting of the open-
label FTY720D2316 trial. Interferon- treatment
was initiated in 2008, but discontinued mid-2010
because of side effects. Her disease course was rela-
tively mild with low frequency and complete recov-
ery of relapses. In March 2011, she presented with a
left-sided hemiparesis, headache, and nausea that had
gradually developed over 2 weeks. Because she had
no clinical signs of infection, an exacerbation of mul-
tiple sclerosis (MS) was considered initially and she
was admitted for IV methylprednisolone treatment.
During the administration of the first dosage, the
hemiparesis progressed and she had 2 partial epilep-
tic seizures with jerks of the left leg, 1 of which gen-
eralized. We discontinued methylprednisolone and
fingolimod and started valproic acid and acyclovir.
New demyelinating lesions, infection (herpes or vari-
cella encephalitis, toxoplasmosis, or brain abscess),
and neoplasm (lymphoma, glioma) were considered
to be possible causes of her symptoms.
Cranial MRI showed 2 large white matter lesions
in the right hemisphere with surrounding vasogenic
edema, mass effect, and open ring enhancement after
gadolinium administration (figure, A). This sug-
gested multifocal tumefactive demyelination, which
was supported by magnetic resonance spectroscopy
(figure, B–D). A pyogenic abscess was unlikely be-
cause of absence of diffusion restriction.
Serologic studies were negative for syphilis, Borre-
lia, HIV, and toxoplasmosis; and cytomegalovirus
(CMV), herpes simplex virus (HSV), varicella-zoster
virus (VZV), and Epstein-Barr virus (EBV) were all
immunoglobulin G positive and immunoglobulin M
negative. In the CSF we found 7 leukocytes/L (0–
4), glucose 3.5 mmol/L (serum glucose 6.4 mmol/L),
protein 1,065 mg/L (0–500). No pathologic cells
were found in the CSF. CSF cultures for bacteria,
mycobacteria, yeast, and fungus were negative. CSF
PCR for mycobacteria, CMV, EBV, HSV-1,
HSV-2, VZV, and JCV was negative.
We discontinued treatment with acyclovir after
viral PCRs returned negative. The patient recovered
within 1 week and was discharged with a slight resid-
ual left-sided hemiparesis.
In the weeks after discharge she recovered com-
pletely. We performed serial follow-up MRI, show-
ing gradual regression and remyelination of the
lesions. Discrete areas of focal demyelination re-
mained. One month after discharge, small new
gadolinium-enhancing lesions were seen, indicating
new inflammatory MS activity (figure, A). This led
us to start glatiramer acetate.
Discussion. Tumefactive demyelination refers to
demyelinating brain lesions mimicking brain neo-
plasm clinically and radiographically. These lesions
are larger than 2 cm, and show vasogenic edema,
mass effect, and variable, typical open ring enhance-
ment after gadolinium administration on MRI.2 Tu-
mefactive demyelination is a rare phenomenon. If
present, it is as the presenting demyelinating event in
61% of cases. Only 5% of tumefactive lesions occur
in established MS.2
Although a causative role of fingolimod on the basis
of one case report is uncertain, the concomitant occur-
rence is noteworthy. First, the time course is suggestive,
as our patient developed tumefactive lesions only a few
months after starting fingolimod, whereas her disease
course had been unexceptional before the start and after
the cessation of fingolimod treatment. Secondly, tume-
factive lesions—particularly if multifocal—in estab-
lished MS are very rare.2
An association between fingolimod and tumefac-
tive demyelination is further supported by reports of
similar cases of patients with MS on fingolimod with
tumefactive lesions,3,4 in one case requiring craniec-
tomy.4 Possibly related are reports concerning a
young woman with a severe MS relapse5 and a man
with neuromyelitis optica spectrum disorder with ex-
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Figure MRI andmagnetic resonance spectroscopy show evolution of multifocal tumefactive demyelination
(A) Axial T2 (top row) and gadolinium-enhanced T1-weightedMRI (bottom row) illustrate the lesion evolution at baseline (February 22, 2008), at the time of
the admission to our hospital (March 15, 2011), and during follow-up (March 29, 2011, May 24, 2011). On March 15, 2011, the patient presented with
multifocal tumefactive lesions in both hemispheres particularly on the right side. One part of the lesion showed a necrotic and cystic appearance on the
T2-weighted images (closed head arrows) and other parts showed signs of active demyelination with disruption of the blood–brain barrier leading to
contrast enhancement (open head arrows). After cessation of immune-modulating treatment, the volume of the demyelinating areas decreased, suggesting
remyelination, and the contrast enhancement disappeared (see MRI of March 29, 2011). However, during follow-up new multiple sclerosis lesions with
active inflammation in terms of contrast enhancement occurred (closed head arrows in the MRI of May 24, 2011). (B) Quantitative chemical shift imaging
(CSI) was performed with PRESS localization (repetition time/echo time 3,000/30 msec), as indicated with large white volume of interest. (C) Top row:
longitudinal spectra from voxel 1 in the cystic/necrotic area. The initial spectrum (March 15, 2011) shows an almost complete absence of all metabolites
except choline-containing compounds (Cho) due tomembrane degradation. It also shows a huge elevation of lactate (Lac) due to inflammatory components,
and of lipids (Lip) consistent with the presence of macrophages. Over time (March 29, 2011, and May 24, 2011), NAA slightly improves but remains low,
due to neuro-axonal loss or damage, whereas creatine (Cr), myo-inositol (Ins), andCho strongly increase due to glial proliferation. Lac has diminished, but Lip
remains very prominent. Bottom row: longitudinal spectra from the surrounding border (voxel 2) are initially characterized by a reduced concentration of all
metabolites, probably due to the diluting effect of edema, and the presence of Lac. Over time, the spectra almost normalize, although NAA remains slightly
reduced and some lipid signals remain visible. (D) Metabolite concentrations (in mmol/L) corresponding to these spectra were quantified with LCModel, and
compared to concentrations in contralateral white matter (WM).
Neurology 79 November 6, 2012 2001
tensive brain lesions and vasogenic edema after start-
ing fingolimod.6 The origin of tumefactive lesions in
patients with MS during fingolimod treatment re-
mains speculative. As fingolimod only prevents the
lymph node egress of subsets of lymphocytes, one
can imagine that in a minority of patients this will
preferentially affect inhibitory immune cells. Fingoli-
mod also has largely unknown effects on astrocytes,
neurons, oligodendrocytes, and microglial cells in the
CNS, which might have unpredictable side effects in
certain individuals.7
A relationship between tumefactive MS lesions
and fingolimod treatment remains uncertain. Al-
though fingolimod is a promising and generally safe
treatment of RRMS, doctors should be alert for
unknown side effects. Precise registration and publi-
cation of these complications during fingolimod
treatment is important.
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VARICELLA-ZOSTER VIRUS ENCEPHALITIS
AND VASCULOPATHY IN A PATIENT TREATED
WITHFINGOLIMOD
A 50-year-old man with multiple sclerosis (MS) was ad-
mitted with a seizure and coma in the setting of herpes
zoster. The patient developed MS in 2003 and was
switched to fingolimod in 2011, 4 months after discon-
tinuing natalizumab (54 doses). He was clinically stable,
but mostly wheelchair-bound with relatively preserved
upper extremity function. Brain MRI obtained before
starting fingolimod was stable. He had a history of
chicken pox, and he had not received the herpes zoster
(shingles) vaccine. Three months after starting fingoli-
mod he developed herpes zoster. Oral valacyclovir was
started 4 days after onset of the rash. Four days after
initiating valacyclovir, the patient had a generalized sei-
zure and was hospitalized. He was deeply comatose and
required intubation. CSF analysis showed 27 leukocytes
(84% lymphocytes, 9% neutrophils, 7% monocytes),
217 erythrocytes, glucose 61 mg/dL (normal 50–75),
and protein 201mg/dL (normal 15–45). CSF varicella-
zoster virus (VZV) PCR was positive, and CSF showed
a low-level positive JC virus PCR in the hospital labora-
tory. PCR tests for herpes simplex virus (HSV), cyto-
megalovirus, Epstein-Barr virus, and enteroviruses were
negative. Absolute lymphocyte count was 190 cells/L
(normal 1,100–4,800). MRI of the brain revealed 2
new punctate areas of restricted diffusion in the postero-
lateral medulla, most consistent with focal infarcts (fig-
ure). His MS lesions were unchanged. Gadolinium was
not administered due to acute renal failure. Magnetic
resonance angiography of the head was normal. He was
diagnosed with VZV encephalitis, seizures, and a brain-
stem infarct believed to be a result of VZV vasculitis.
There was no clinical evidence of PML. He was treated
with levetiracetam, IV acyclovir for 21 days, and pred-
nisone 1 mg/kg daily for 7 days for VZV vasculitis.
During a complex hospitalization he slowly improved,
and 1 month later he was awake and oriented with sig-
nificant psychomotor slowing and persistent quadripa-
resis in this patient who was wheelchair-bound at
baseline. He was transferred to a rehabilitation hospital
for continued ventilator weaning. The case was re-
ported to the Food andDrug Administration (viaMed-
Watch) and to Novartis.
Discussion. This patient developed herpes zoster in
the setting of fingolimod-related lymphopenia,
which progressed to VZV encephalitis and multifo-
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